Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
2 Adrenergic signaling in cardiomyocytes 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
3 Alcoholic liver disease 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
4 Aldosterone synthesis and secretion 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
5 Aldosterone synthesis and secretion 💬
 1件: MC2R 💬 D00146 💬 Corticotropin 12件:  2 , 13, 14, 46, 49, 50, 66, 75, 81, 84, 145, 222 💬
6 Aldosterone-regulated sodium reabsorption 💬
 1件: NR3C2 💬 D07967 💬 Fludrocortisone 3件:  6 , 17, 81 💬
7 Alzheimer disease 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
8 Amphetamine addiction 💬
 2件: CACNA1C, CACNA1D 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
9 AMPK signaling pathway 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
10 AMPK signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
11 Apelin signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
12 Arrhythmogenic right ventricular cardiomyopathy 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
13 Autophagy - animal 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
14 Calcium signaling pathway 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
15 cAMP signaling pathway 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
16 cAMP signaling pathway 💬
 1件: MC2R 💬 D00146 💬 Corticotropin 12件:  2 , 13, 14, 46, 49, 50, 66, 75, 81, 84, 145, 222 💬
17 Carbohydrate digestion and absorption 💬
 1件: CACNA1D 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
18 Cardiac muscle contraction 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
19 Cellular senescence 💬
 1件: CACNA1D 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
20 cGMP-PKG signaling pathway 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
21 Chemical carcinogenesis - receptor activation 💬
 1件: AR 💬 D00586 💬 Flutamide 1件: 81 💬
22 Chemical carcinogenesis - receptor activation 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
23 Cholinergic synapse 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
24 Circadian entrainment 💬
 2件: CACNA1C, CACNA1D 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
25 Circadian rhythm 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
26 Cortisol synthesis and secretion 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
27 Cortisol synthesis and secretion 💬
 1件: MC2R 💬 D00146 💬 Corticotropin 12件:  2 , 13, 14, 46, 49, 50, 66, 75, 81, 84, 145, 222 💬
28 Cushing syndrome 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
29 Cushing syndrome 💬
 1件: MC2R 💬 D00146 💬 Corticotropin 12件:  2 , 13, 14, 46, 49, 50, 66, 75, 81, 84, 145, 222 💬
30 Dilated cardiomyopathy 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
31 Dopaminergic synapse 💬
 2件: CACNA1C, CACNA1D 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
32 Fluid shear stress and atherosclerosis 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
33 FoxO signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
34 GABAergic synapse 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
35 Glucagon signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
36 Glutamatergic synapse 💬
 2件: CACNA1C, CACNA1D 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
37 GnRH secretion 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
38 GnRH signaling pathway 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
39 Growth hormone synthesis, secretion and action 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
40 Huntington disease 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
41 Hypertrophic cardiomyopathy 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
42 Hypertrophic cardiomyopathy 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
43 Insulin resistance 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
44 Insulin secretion 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
45 Insulin signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
46 Lipid and atherosclerosis 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
47 Long-term potentiation 💬
 1件: CACNA1C 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
48 Longevity regulating pathway 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
49 Longevity regulating pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
50 Longevity regulating pathway - multiple species 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
51 MAPK signaling pathway 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
52 Metabolic pathways 💬
 1件: CYP19A1 💬 D00964 💬 Letrozole 2件: 81, 89 💬
53 mTOR signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
54 Neuroactive ligand-receptor interaction 💬
 1件: MC2R 💬 D00146 💬 Corticotropin 12件:  2 , 13, 14, 46, 49, 50, 66, 75, 81, 84, 145, 222 💬
55 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D07749 💬 Cortisone 1件: 81 💬
56 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00973 💬 Cortisone acetate 1件: 81 💬
57 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00292 💬 Dexamethasone 22件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299 💬
58 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00088 💬 Hydrocortisone 10件:  6 , 41, 46, 53, 75, 78, 81, 83, 97, 299 💬
59 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00976 💬 Hydrocortisone cypionate 3件:  6 , 81, 83 💬
60 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D01442 💬 Hydrocortisone succinate 3件:  6 , 81, 83 💬
61 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00472 💬 Prednisolone 42件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
62 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00473 💬 Prednisone 45件:  2 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 💬
63 Non-alcoholic fatty liver disease 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
64 Non-alcoholic fatty liver disease 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
65 Oocyte meiosis 💬
 1件: AR 💬 D00586 💬 Flutamide 1件: 81 💬
66 Osteoclast differentiation 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
67 Ovarian steroidogenesis 💬
 1件: CYP19A1 💬 D00964 💬 Letrozole 2件: 81, 89 💬
68 Oxytocin signaling pathway 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
69 Oxytocin signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
70 Pathways in cancer 💬
 1件: AR 💬 D00586 💬 Flutamide 1件: 81 💬
71 Pathways in cancer 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
72 Pathways of neurodegeneration - multiple diseases 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
73 PI3K-Akt signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
74 PPAR signaling pathway 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
75 Prion disease 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
76 Prostate cancer 💬
 1件: AR 💬 D00586 💬 Flutamide 1件: 81 💬
77 Renin secretion 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
78 Retrograde endocannabinoid signaling 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
79 Serotonergic synapse 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
80 Steroid hormone biosynthesis 💬
 1件: CYP19A1 💬 D00964 💬 Letrozole 2件: 81, 89 💬
81 Taste transduction 💬
 1件: CACNA1C 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
82 Thermogenesis 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
83 Thermogenesis 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
84 Thyroid cancer 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
85 Tight junction 💬
 1件: CACNA1D 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
86 Tight junction 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
87 Transcriptional misregulation in cancer 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
88 Type II diabetes mellitus 💬
 2件: CACNA1C, CACNA1D 💬 D00437 💬 Nifedipine 2件: 50, 81 💬
89 Vascular smooth muscle contraction 💬
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 D00437 💬 Nifedipine 2件: 50, 81 💬

先頭へ